Risk factor of liver metastases in breast cancer
Open Access
- 11 December 2019
- journal article
- Published by Heighten Science Publications Corporation
- Vol. 3 (1), 063-065
- https://doi.org/10.29328/journal.acst.1001011
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancerAnnals of Oncology, 2012
- Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcomeAnnals of Oncology, 2011
- Clinical Course of Breast Cancer Patients With Metastases Limited to the Liver Treated With ChemotherapyThe Cancer Journal, 2008
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast CancerJournal of Clinical Oncology, 2007
- CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trialsAnnals of Oncology, 2007
- Prognostic factors for patients with hepatic metastases from breast cancerBritish Journal of Cancer, 2003
- Diagnostic value of HepPar1, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytologyDiagnostic Cytopathology, 2003
- Serum levels of bone alkaline phosphatase in breast and prostate cancers with bone metastasisIndian Journal of Clinical Biochemistry, 2000
- Significance of Bone Alkaline Phosphatase, CA 15-3 and CEA in the Detection of Bone Metastases During the Follow-Up of Patients Suffering from Breast Carcinomacclm, 1992
- ASSESSMENT OF BIOCHEMICAL TESTS TO SCREEN FOR METASTASES IN PATIENTS WITH BREAST CANCER*1The Lancet, 1980